Clinical Trials Logo

Filter by:
NCT ID: NCT05597384 Recruiting - Colorectal Cancer Clinical Trials

Assessment of Autologous Blood Marker Localization in Laparoscopic Colorectal Cancer Surgery

ABILITY
Start date: November 1, 2022
Phase: N/A
Study type: Interventional

Laparoscopic colorectal surgery has been proved to have similar oncological outcomes with open surgery. Due to the lack of tactile perception, surgeons may have misjudgments in laparoscopic colorectal surgery. Therefore, the accurate localization of a tumor before surgery is important, especially in the early stages of cancer. Recently, some retrospective studies reported the use of patients' autologous blood for preoperative colonic localization in colorectal cancer with successful detection by laparoscopy, but its benefits remain controversial. This study aimed to assess the accuracy and safety of autogenous blood marker localization in laparoscopic radical resection for colorectal cancer.

NCT ID: NCT05597150 Completed - Healthy State Clinical Trials

The Exploration of the Regulatory Effect of Magnesium on Intestinal Flora in Healthy Adults

Start date: October 15, 2022
Phase: N/A
Study type: Interventional

In this A Single-center, Prospective, Self-controlled trial, subjects should avoid a high-magnesium diet for 1-3 weeks and take magnesium supplements for 4-6 weeks.

NCT ID: NCT05597137 Completed - Healthy Clinical Trials

The Exploration of the Regulatory Effect of Zinc on Intestinal Flora in Healthy Adults

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

In this A Single-center, Prospective, Self-controlled trial, subjects should avoid a high-Zinc diet for weeks 1-2 and take Zinc supplements for weeks 3-4

NCT ID: NCT05596981 Recruiting - Clinical trials for Allogeneic Hematopoietic Stem Cell Transplantation

The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT

Start date: October 1, 2022
Phase:
Study type: Observational

This prospective trial investigates the effect of sorafenib maintenance therapy in FLT3-ITD AML patients after allo-HSCT in terms of gut microbiome.

NCT ID: NCT05596968 Recruiting - Clinical trials for Allogeneic Hematopoietic Stem Cell Transplantation

The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT

Start date: October 1, 2022
Phase:
Study type: Observational

This prospective trial investigates the effect of sorafenib maintenance therapy in FLT3-ITD positive AML patients after allo-HSCT in terms of gut microbiome.

NCT ID: NCT05596890 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients

PICCRT
Start date: November 30, 2022
Phase: Phase 2
Study type: Interventional

Preoperative Immune checkpoint inhibitors combined with chemotherapy have revolutionized the treatment landscape of locally advanced esophageal squamous cell carcinoma. However, there are still a significant proportion of patients who could not benefit from such treatment modality. Currently, no effective biomarkers were identified to stratify responders and non-responders. Early dynamic and persistent relief of dysphagia may act as a predictive biomarker to reflect the on-treatment anti-tumor activity. In this prospective study, we aimed to explore the feasibility of using patient-reported outcomes (PROs) to predict the pathological complete response of esophageal squamous cell carcinoma patients treated with neoadjuvant immunochemotherapy with or without short-term radiation as well as to assess the efficacy and safety of short-term radiotherapy in PROs-insensitive patients after one cycle of neoadjuvant immunochemotherapy.

NCT ID: NCT05596747 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus

Start date: November 30, 2022
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety of a study drug known as LY3209590 in Chinese participants with type 2 diabetes mellitus who are on a stable dose of basal insulin. Side effects and tolerability will be documented. Blood samples will be taken to assess how the body processes the study drug and the effect of the study drug on blood sugar levels. The study will last up to 18 weeks and may include 18 visits for each participant.

NCT ID: NCT05596721 Not yet recruiting - Asthma Clinical Trials

Azithromycin Treatment for Non-eosinophilic Chest Tightness Variant Asthma

Start date: January 1, 2023
Phase: Phase 4
Study type: Interventional

Bronchial asthma (abbr. asthma) is one of common airway chronic inflammatory disease which usually threatens human health. Typical symptoms of asthma are recurrent wheezing, shortness of breath, chest tightness and cough, usually happened at night or in early morning. However, there are still some patients who persist only clinical manifestations of chest tightness, namely, chest tightness variant asthma (CTVA). This subgroup of asthma usually lacks asthma-specific clinical features, therefore, often misdiagnosed and lack of effective treatment for a long time. The investigators' previous studies have found that CTVA has eosinophilic and non-eosinophilic subtypes. These patients with non-eosinophilic CTVA (NE-CTVA) are not sensitive to ICS/LABA, which guidelines recommend. At present, the specific treatment plan for NE-CTVA is urgently needed to elucidate. Azithromycin has immunomodulatory and anti-inflammatory effects in addition to their antibacterial effects. Maintenance treatment with azithromycin has been proved to be effective in chronic neutrophilic airway diseases and severe asthma. However, there are no clinical studies to confirm the effectiveness of azithromycin in non-eosinophilic asthma, especially atypical asthma such as NE-CTVA. Now the investigators performed a national multi-center study to explore whether azithromycin improves asthma symptom control and improves quality of life in people with NE-CTVA. Finally, to find an optimal treatment for NE-CTVA.

NCT ID: NCT05596708 Not yet recruiting - IgA Nephropathy Clinical Trials

Study of Telitacicept in Patients With Refractory IgA Nephropathy

Start date: March 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical trial is to explore the effectiveness and safety of Telitacicept in adults with refractory IgA nephropathy. The main questions it aims to answer are: - To evaluate the clinical efficacy of Telitacicept in patients with refractory IgA nephropathy. - To evaluate the safety and adverse reaction of Telitacicept in patients with refractory IgA nephropathy. Participants will be subcutaneously injected with 240mg of Telitacicept once per week. Study subject: After 6 months of sequential treatment with renin-angiotensin system (RAS) blockers or glucocorticoids, patients with pathological biopsy of 0.7≥5 g/24 hours of proteinuria was confirmed as refractory IgA nephropathy.

NCT ID: NCT05596630 Recruiting - Clinical trials for Carcinoma; Hepatocellular

Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC

Start date: May 8, 2023
Phase: N/A
Study type: Interventional

Primary liver cancer is one of the common malignant tumors in China, of which hepatocellular carcinoma (HCC) accounts for 85%-90%. It is worth noting that the recurrence rate of liver cancer is greater than 10% at 1 year after surgery, while the recurrence rate in 5 years reaches 70-80%. Stereotactic body radiation therapy (SBRT) refers to a kind of radiotherapy technology to achieve a steep dose gradient and achieve high-precision position and high-dose fractionated irradiation. The rapid dose drop-down enables SBRT to maximize the protection of normal tissues around the tumor, and it often requires only 1-5 times of high-dose fractionated irradiation to complete the course of treatment.SBRT may play an important role in the treatment of small intrahepatic recurrence HCC, but there is still a lack of evidence of high-level prospective studies. We intend to conduct a single-center, prospective, clinical study to further elaborate the efficacy and safety of SBRT in the treatment of small intrahepatic recurrent HCC.